Innate Pharma announces the full exercise of the over-allotment option granted to the guaranteeing banks for its capital increase and its IPO on the nasdaq global select market allowing the subscription of 1,875,000

0
8


THIS PRESS RELEASE IS NOT INTENDED FOR PUBLICATION, DISTRIBUTION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO THE UNITED STATES OF AMERICA OR TO AMERICAN NATIONALS (" U.S. PERSONS FOR THEIR BENEFIT OR FOR THEIR ACCOUNT (AS DEFINED IN THE REGULATION S ON THE BASIS U.S. SECURITIES ACT OF 1933), AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION OR THE OFFER OR SALE OF SECURITIES ARE OR ARE PROHIBITED BY APPLICABLE LAW.

INNATE PHARMA ANNOUNCES THE FULL YEAR OF THE OVERALLOCATION OPTION GRANTED TO THE GUARANTEED BANKS OF ITS INCREASE IN CAPITAL AND ITS LISTING ON THE NASDAQ GLOBAL SELECT MARKET TO SUBSCRIBE 1 875 000 ADSs SUPPLEMENTARY

Marseille, October 18, 2019, 4 pm

INNATE PHARMA S.A. (the Society – Euronext Paris: FR0010331421 – IPH), a French biotechnology company specializing in the discovery, development and commercialization of "first-in-class" therapeutic antibodies exploiting the immune system to treat cancers in dire medical need, announced today the banks guaranteeing the capital increase of 12,500,000 new shares, including an offer to the public of 8,047,227 ordinary shares in the form ofAmerican Depositary Shares ( ' ADSs Each of which represents one common share and one concurrent private placement of 4,452,773 common shares in Europe (including France) and in other countries outside the United States (the " Global Offer ") Exercised the entire over-allotment option allowing them to subscribe for 1,875,000 additional new shares to be delivered in the form of ADSs. Settlement will occur at the same time as the initial capital increase.

As a result, the total number of Company Shares and ADSs issued under the Global Offering is 14,375,000 shares, of which 9,922,227 will be delivered in the form of ADSs, thus increasing the size of the Offer. of the transaction at approximately $ 79.1 million, equivalent to 71.4 million euros1.

In addition, Citigroup Global Markets Inc., in its capacity as a stabilizing agent, declares that no stabilization transaction has been completed. The period during which stabilization operations could be carried out ends today.

This press release does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction, and may not be construed as an offer, solicitation or sale in any jurisdiction in any jurisdiction. any offer, solicitation or sale would be illegal prior to registration or certification in accordance with local regulations.

About Innate Pharma:

Innate Pharma S.A. is a commercial biotechnology company specializing in immuno-oncology, dedicated to improving the treatment of cancers through innovative therapeutic antibodies exploiting the immune system.

Innate Pharma's Lumoxiti commercial product, licensed to AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in-class oncology product for the treatment of hairy cell leukemia (LT) ). Innate Pharma's broad portfolio of antibodies includes several potentially "first-in-class" candidates at the clinical and preclinical stage in cancers where the medical need is high.

A pioneer in NK cell biology, Innate Pharma has expanded its expertise in the tumor microenvironment and targeting of tumor antigens, as well as in antibody engineering. Innate Pharma's approach has enabled it to form alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A / S or Sanofi, as well as a multi-product partnership with AstraZeneca.

Innate Pharma is a company listed on Compartment B of the Euronext Paris Regulated Market (Euronext: IPH – ISIN: FR0010331421).

Warning :

Investors' attention is drawn to section 3 "Risk Factors" of the Universal Registration Document filed with the Autorite des marches financiers (AMF) on September 20, 2019, available on the websites of Innate Pharma (www.innate-pharma.com) and the AMF (www.amf-france.org). Subject to applicable regulations, the Company makes no commitment to update or revise the information contained herein. This press release was produced in French and English; if there is a difference between the texts, the French version will prevail.

For further information, please contact:

Important information:

This press release constitutes a promotional communication and not a prospectus within the meaning of Regulation (EU) 2017/1129 ("the Regulation Prospectus "). The admission prospectus, once approved by the AMF, will be available on the website of the Company (www.innate-pharma.com) and on the AMF website (www.amf-france.org).

European Economic Area :

No action has been taken and will be undertaken to offer the shares of the Company to a retail investor established in the European Economic Area as part of the Global Offer. For the purposes of this paragraph:

  1. "retail investor" means a person in one (or more) of the following categories:
    1. a retail customer as defined in point (11) of Article 4 (1) of Directive 2014/65 / EU (as amended, MiFID II "); or
    2. a customer within the meaning of Directive 2016/97 / EU as amended, when that customer is not qualified as a professional client within the meaning of point (10) of Article 4 (1) of MiFID II; or
    3. a person other than a "qualified investor" as defined by the Prospectus Regulation; and
  2. the expression " offer "Refers to any communication in any form and by any means to persons with sufficient information on the terms of the offer and the securities of the Company to be offered, so as to enable an investor to decide to buy or subscribe for these securities.

France :

The shares of the Company in the context of the Global Offer will neither be offered nor sold, directly or indirectly, to the public in France to persons other than qualified investors. Any offer or transfer of shares in the Company or distribution of offering documents has been and will be made in France only to qualified investors as defined by Article 2 (e) of the Prospectus Regulation and in accordance with with Articles L. 411-1 and L. 411-2 of the Monetary and Financial Code.

UK :

This press release is addressed only to (i) persons who are located outside the United Kingdom, (ii) investment professionals (" investment professionals Within the meaning of Article 19 (5) of Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (" Order (Iii) to persons covered by section 49 (2) (a) to (d) ("high-capital corporations, unregistered associations, etc.") of the Ordinance, or (iv) to any other person to whom this press release may be addressed in accordance with the law (the persons mentioned in paragraphs (i), (ii), (iii) and (iv) being together referred to as " Empowered Persons "). The shares of the Company offered under the Global Offer are intended only for Qualified Persons and any invitation, offer or any contact relating to the subscription, purchase or acquisition of the shares of the Company within the framework of the Offer. Global Offer may only be addressed or concluded with Qualified Persons. Anyone other than an Empowered Person must refrain from using or relying on this release and the information contained therein.

This press release does not constitute a prospectus approved by the Financial Services Authority or by any other regulatory authority in the United Kingdom within the meaning of Section 85 of the Ordinance.


1 On the basis of the exchange rate published on 16 October 2019 of 1 euro = 1.1065 U.S. dollars



Source link
https://www.zonebourse.com/INNATE-PHARMA-35620/actualite/Innate-Pharma-annonce-l-exercice-integral-de-l-option-de-surallocation-accordee-aux-banques-garant-29416970/

Dmca

LEAVE A REPLY

Please enter your comment!
Please enter your name here

fourteen − 10 =